



The Innate and Adaptive T cell Response to SARS-CoV-2

Sinead Cummins, Stefan Elekes, Kiran Singh, Derek Doherty
Trinity Translational Medicine Institute, St. James' Hospital, Dublin, Ireland

Background

- Understanding innate and adaptive immunity to SARS-CoV-2 is important for understanding the pathogenesis of COVID-19, vaccine development and pandemic response measures¹.
- Critical (ICU) and fatal COVID-19 outcomes are associated with elevated levels of inflammatory mediators² and impairments in T cells.
- $\gamma\delta$ T cells are thought to be involved in immunity against SARS-CoV-2 or pathogenesis of severe COVID-19:
 - Severe COVID-19 patients have pronounced reductions in circulating $\gamma\delta$ T cells.
 - Evidence suggests activation of $\gamma\delta$ T cells and infiltration of V δ 2 T cells in the lungs of COVID-19 patients³.
- There are four major structural SARS-CoV-2 proteins: spike, nucleocapsid, membrane, and envelope (Figure 1).
- We investigated if the most immunogenic SARS-CoV-2 proteins, Spike and Nucleocapsid, can activate the 2 most abundant subsets of $\gamma\delta$ T cells – V δ 1 and V δ 2 T cells, either directly or presented by dendritic cells (DCs).




Figure 1: SARS-CoV-2 Structural Proteins

Aims

- Determine if DCs are activated by stimulation with spike and nucleocapsid peptides.
- Determine if $\gamma\delta$ T cells respond to spike and nucleocapsid proteins presented by DCs.
- Determine the magnitude and nature of cytokine release in response to SARS-CoV-2 spike and nucleocapsid proteins by flow cytometry.

Methods

- $\gamma\delta$ T cell lines and DCs were generated from peripheral blood mononuclear cells (PBMCs) isolated from blood packs from the Irish Blood Transfusion Service.
- The DCs were stimulated with SARS-CoV-2 spike protein and nucleocapsid protein from two sources (Raybiotech (RB) and Prof. Seamus Martin (SM)) and control stimuli (LPS, Curdlan, Poly I:C) and the expression of markers of antigen presentation and production of cytokines was analysed by flow cytometry.
- $\gamma\delta$ T cells were co-cultured with SARS-CoV-2 stimulated DCs and analysed by flow cytometry for cytokine production.




Figure 2: Method Summary Diagram

Results

- SARS-CoV-2 nucleocapsid, but not spike, protein induced weak expression of HLA-DR, CD40 and CD83, but not CD86 by DCs (Figure 3).
- SARS-CoV-2 nucleocapsid protein induced the production of IL-12 and TNF- α , but not IL-10 or IL-23, by DCs, however these increases were not significant (Figure 4).
- DCs pulsed with SARS-CoV-2 nucleocapsid, but not spike, protein significantly induced the production of IFN- γ , but not IL-17 or TNF- α by V δ 1 and V δ 2 T cells (Figure 5).
- The stimulatory effects of SARS-CoV-2 nucleocapsid protein for DCs and V δ 1 and V δ 2 T cells was not abrogated by digestion with V8 protease (Figure 6).
- The stimulatory effects of SARS-CoV-2 RB-nucleocapsid protein were not observed with a second source of nucleocapsid protein (SM-nucleocapsid) (Figure 7).
- Peptide fragments of SARS-CoV-2 spike and nucleocapsid that stimulate conventional T cells did not activate cytokine production by DCs or V δ 1 or V δ 2 T cells (Figure 8).





Figure 3: Effect of SARS-CoV-2 spike and nucleocapsid proteins on DC maturation. (A) Representative flow cytometry plots show HLA-DR expression by CD11c⁺ cells. (B-E) Scatter plots show the fold change in mean fluorescence intensity (MFI) of HLA-DR, CD40, CD83 & CD86 expression by DCs after each treatment over the MFI of these markers on unstimulated DCs (medium). MFI fold change was statistically compared using the Mann-Whitney U test.





Figure 4: Effect of SARS-CoV-2 spike and nucleocapsid proteins on cytokine production by DCs. (A) Representative flow cytometry plots show IL-12 expression by CD11c⁺ cells (DCs). (B-E) Scatterplots show percentage positive IL10, IL-12, IL-23 & TNF- α DCs after treatment. Cytokine positivity is statistically compared using the Mann-Whitney U test.






Figure 5: Effect of DCs treated with SARS-CoV-2 spike and nucleocapsid proteins on cytokine production by $\gamma\delta$ T cells. (A) Representative flow cytometry plots show IFN- γ and TNF- α expression after gating on V δ 1 T cells. (B-G) Scatterplots show percentage positive IFN- γ , IL-17 or TNF- α cells for V δ 1 or V δ 2 T cells in the presence of DCs. Cytokine positivity of $\gamma\delta$ T cells was statistically compared using the Mann-Whitney U test.





Figure 6: Effect of V8 protease treatment on stimulatory activity by RB-nucleocapsid protein. (A) Flow cytometry plots showing IL-12 expression by CD11c⁺ cells after treatment with undigested and V8 protease-digested RB-nucleocapsid protein. (B) IFN- γ and TNF- α expression after gating on V δ 1 T cells after treatment with and without V8 protease. (C) Scatterplots show percentage positive IL-12 DCs combined across all experiments. (D,E) Scatter plots show percentage IFN- γ positive V δ 1 and V δ 2 T cells. Cytokine positivity of cells was statistically compared using the Mann-Whitney U test.





Figure 7: Effect of SARS-CoV-2 SM-Nucleocapsid protein on cytokine production by DCs and $\gamma\delta$ T cells. (A) Representative flow cytometry plots show IL-12 expression by CD11c⁺ cells. (B) Flow cytometry dot plots show IFN- γ and TNF- α cells for V δ 1 T cells. (C) Scatterplot shows IL-12 positive DCs co-cultured with $\gamma\delta$ T cells. (D-E) Scatterplots show percentage IFN- γ V δ 1 or V δ 2 T cells in the presence of DCs. Cytokine positivity of cells was statistically compared using the Mann-Whitney U test.




Figure 8: Effect of SARS-CoV-2 peptides on DCs and $\gamma\delta$ T cell cytokine production. (A) Scatterplot showing percentage IL-12 positive DCs stimulated with pools of peptides derived from spike (S, S1 and S2) and nucleocapsid (N) proteins in the presence of $\gamma\delta$ T cells. (B,C) Scatter plots show percentage IFN- γ V δ 1 or V δ 2 T cells in the presence of the peptide-pulsed DCs. Cytokine positivity was statistically compared using the Mann-Whitney U test.

Discussion

- Several studies have suggested that $\gamma\delta$ T cells are involved in immunity against SARS-CoV-2. $\gamma\delta$ T cells play crucial roles in frontline immunity against viruses through their rapid activation, cytotoxic response and cytokine release. They accumulate in the mucosal epithelia⁴ and are depleted in severe COVID-19 patients⁵.
- A previous study from our group showed that SARS-CoV-2 spike and nucleocapsid proteins do not directly activate $\gamma\delta$ T cells.
- In the present study, SARS-CoV-2 nucleocapsid, but not spike protein induced DC maturation and cytokine production and these nucleocapsid-treated DCs promoted cytokine production by V δ 1 and V δ 2 T cells.
- However, protease digestion of the nucleocapsid protein did not abrogate its stimulatory activity, suggesting that the DC and $\gamma\delta$ T cell activation by SARS-CoV-2 nucleocapsid is due to a non-protein contaminant, such as LPS.
- While SARS-CoV-2 nucleocapsid protein purchased from RayBiotech (RB-nucleocapsid) activated DCs and $\gamma\delta$ T cells, treatment with SARS-CoV-2 nucleocapsid from a second source (SM-nucleocapsid) did not, further suggesting that the RB-nucleocapsid is contaminated with LPS.
- Sets of immunogenic SARS-CoV-2 spike and nucleocapsid peptides did not activate DCs V δ 1 or V δ 2 cells.

Conclusion

- SARS-CoV-2 spike and nucleocapsid proteins do not appear to activate DCs.
- SARS-CoV-2 spike and nucleocapsid proteins do not appear to activate $\gamma\delta$ T cells in the presence of DCs.

References

- Alba Grifoni, Daniela Weiskopf et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*, Volume 181, Issue 7, 2020, Pages 1489-1501.e15. <https://doi.org/10.1016/j.cell.2020.08.009>
- E.J. Giamarellos-Bourboulis, M.G. Netea, N. Rovina, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host Microbe* (2020), [10.1016/j.chom.2020.08.009](https://doi.org/10.1016/j.chom.2020.08.009)
- Niklas K Björkstén, Andrea Ponzetta, Natural killer cells and unconventional T cells in COVID-19. *Current Opinion in Virology*, Volume 45, 2021, Pages 176-182, <https://doi.org/10.1016/j.coviro.2021.06.005>
- Chen, X. J., Li, K., Xu, L., Yu, Y. J., Wu, B., He, Y. L., Zhou, W. E., Li, D., Luan, C. H., Xu, L., Wang, J., Ding, J. J., Yu, Y. F., Li, X., Tan, Z. M., Liu, X. F., Wei, D., Zhang, Z. H., Guo, X. J., Su, C., Hu, Z. B., Guo, Y. S., Chen, J. Y., & Chen, F. (2021). Novel insight from the first lung transplant of a COVID-19 patient. *European Journal of Clinical Investigation*, 51(1). <https://doi.org/10.1111/eji.13443>
- Zhou, R., To, K. K., Wong, Y. C., Liu, L., Zhou, B., Li, X., Huang, H., Mo, L., Lu, T. Y., Lau, T. T., Yeung, P., Chan, W. M., Wu, A. K., Lung, K. C., Tsang, O. T., Leung, W. S., Hung, I. F., Yuen, K. Y., & Chen, Z. (2020, Oct 13). Acute SARS-CoV-2 infection impairs Dendritic Cell and T Cell Responses. *Immunity*, 53(4), 864-877.e865. <https://doi.org/10.1016/j.immuni.2020.07.026>

Acknowledgements

I would like to thank the Laidlaw Undergraduate Research and Leadership Programme for funding of this work, my supervisor Prof. Derek Doherty for his mentorship and guidance throughout the project and Joel McKeever and Orla Bannon in the Careers office for their ongoing support. I would also like to thank Kiran Singh and Stefan Elekes for working alongside me in this project. Many thanks also to Prof. Seamus Martin and Dr. Zaneta Najda for providing the SM nucleocapsid protein.